Patents Assigned to Mochida Pharmaceutical Co., Ltd.
  • Publication number: 20170273929
    Abstract: The present invention provides the following: a cardiovascular disease primary prevention agent, which comprises as the active ingredient at least one selected from the group consisting of EPA, salts thereof, and esters thereof and is for lowering the risk of cardiovascular disease by administration to subjects having a blood (serum or plasma) hs-CRP level of 1.0 mg/L or higher in spite of no history of cardiovascular disease; a combination marker comprising the blood hs-CRP value and serum EPA/AA ratio for evaluating the primary risk of cardiovascular disease in subjects having no history of cardiovascular disease; and a method for extracting subjects with high risk of cardiovascular disease and/or a method for preventing cardiovascular disease.
    Type: Application
    Filed: June 9, 2017
    Publication date: September 28, 2017
    Applicants: MOCHIDA PHARMACEUTICAL CO., LTD., KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION
    Inventors: Yutaka KIYOHARA, Toshiharu NINOMIYA, Takashi YANO
  • Publication number: 20170217958
    Abstract: The present invention provides a method for manufacturing a compound represented by formula (I). With this method, provided are a method for manufacturing a 4-heteroaryl-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-5-carboxylic acid amide derivative; and an intermediate for this manufacturing method.
    Type: Application
    Filed: July 29, 2015
    Publication date: August 3, 2017
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Tsutomu SATOH, Takashi KUDOH, Tetsuo IWAMA
  • Publication number: 20170210740
    Abstract: The present invention provides a method for manufacturing a compound represented by formula (I). With this method, provided is a method for manufacturing a 4-substituted-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-5-carboxylic acid amide derivative; or an intermediate for this manufacturing method.
    Type: Application
    Filed: July 29, 2015
    Publication date: July 27, 2017
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Tsutomu SATOH, Takashi KUDOH, Tetsuo IWAMA
  • Patent number: 9700537
    Abstract: Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: July 11, 2017
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito
  • Patent number: 9700538
    Abstract: The present invention provides the following: a cardiovascular disease primary prevention agent, which comprises as the active ingredient at least one selected from the group consisting of EPA, salts thereof, and esters thereof and is for lowering the risk of cardiovascular disease by administration to subjects having a blood (serum or plasma) hs-CRP level of 1.0 mg/L or higher in spite of no history of cardiovascular disease; a combination marker comprising the blood hs-CRP value and serum EPA/AA ratio for evaluating the primary risk of cardiovascular disease in subjects having no history of cardiovascular disease; and a method for extracting subjects with high risk of cardiovascular disease and/or a method for preventing cardiovascular disease.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: July 11, 2017
    Assignees: MOCHIDA PHARMACEUTICAL CO., LTD., KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION
    Inventors: Yutaka Kiyohara, Toshiharu Ninomiya, Takashi Yano
  • Patent number: 9695198
    Abstract: The present invention provides a compound of Formula (I) where A is a heterocycle ring system and B is a heterocycle ring system or aryl ring system, and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: July 4, 2017
    Assignees: Merck Sharp & Dohme Corp., Mochida Pharmaceutical Co., Ltd.
    Inventors: Cameron James Smith, Edward Sherer, Louis-Charles Campeau, James Balkovec, William John Greenlee, Derun Li, Liangqin Guo, Tin-Yau Chan, Yi-Heng Chen, Yili Chen, Samuel Chackalamannil, John Qiang Tan, Tomokazu Hirabayashi, Mika Sekioka
  • Publication number: 20170151178
    Abstract: It has been desired to develop a coating composition, which is used for an orally-administered preparation having an improved administering property, and/or an easily administrable preparation that does not affect dissolution property. The present invention provides a coating composition comprising: a first thickener selected from the group consisting of a carboxyvinyl polymer and sodium alginate; a polyvalent metal compound; at least one type of a second thickener selected from the group consisting of xanthan gum, guar gum and sodium alginate, with the proviso that when the first thickener is sodium alginate the second thickener is not sodium alginate; and sucralose.
    Type: Application
    Filed: January 31, 2017
    Publication date: June 1, 2017
    Applicant: Mochida Pharmaceutical Co., Ltd.
    Inventors: Yumio KUDOU, Kuniomi WARABINO, Hiromitsu ITO
  • Publication number: 20170151206
    Abstract: Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.
    Type: Application
    Filed: February 14, 2017
    Publication date: June 1, 2017
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Mitsuhiro YOKOYAMA, Hideki ORIGASA, Masunori MATSUZAKI, Yuji MATSUZAWA, Yasushi SAITO
  • Publication number: 20170119724
    Abstract: This invention provides a self-emulsifying composition comprising 50 to 95% by weight in total of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; and 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10. The composition has no or reduced ethanol content, and exhibits excellent self-emulsifying property, dispersibility in the composition, emulsion stability, and absorption property. The composition is adapted for use as a drug.
    Type: Application
    Filed: January 18, 2017
    Publication date: May 4, 2017
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Hirosato FUJII, Motoo YAMAGATA
  • Patent number: 9603805
    Abstract: It has been desired to develop a coating composition, which is used for an orally-administered preparation having an improved administering property, and/or an easily administrable preparation that does not affect dissolution property. The present invention provides a coating composition comprising: a first thickener selected from the group consisting of a carboxyvinyl polymer and sodium alginate; a polyvalent metal compound; at least one type of a second thickener selected from the group consisting of xanthan gum, guar gum and sodium alginate, with the proviso that when the first thickener is sodium alginate the second thickener is not sodium alginate; and sucralose.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: March 28, 2017
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Yumio Kudou, Kuniomi Warabino, Hiromitsu Ito
  • Publication number: 20170079946
    Abstract: A medical composition for reducing the rate of new-onset diabetes caused by administration of a statin or for inhibiting an increase in blood glucose level by administration of a statin, the composition containing at least one ingredient selected from the group consisting of icosapentaenoic acid and pharmaceutically acceptable salts or esters thereof as an inactive ingredient.
    Type: Application
    Filed: November 30, 2016
    Publication date: March 23, 2017
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Masahiko OHTA, Shinichi OIKAWA, Mitsuhiro YOKOYAMA, Hideki ORIGASA, Masunori MATSUZAKI, Yuji MATSUZAWA, Yasushi SAITO
  • Patent number: 9579281
    Abstract: This invention provides a self-emulsifying composition comprising 50 to 95% by weight in total of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; and 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10. The composition has no or reduced ethanol content, and exhibits excellent self-emulsifying property, dispersibility in the composition, emulsion stability, and absorption property. The composition is adapted for use as a drug.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: February 28, 2017
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Hirosato Fujii, Motoo Yamagata
  • Publication number: 20170027916
    Abstract: In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Application
    Filed: April 10, 2015
    Publication date: February 2, 2017
    Applicants: Merck Sharp & Dohme Corp., Mochida Pharmaceutical Co., Ltd.
    Inventors: Isao Sakurada, Tomokazu Hirabayashi, Yoshitaka Maeda, Hiroshi Nagasue, Takashi Mizuno, Jiayi Xu, Ting Zhang, Cameron Smith, Dann Parker
  • Patent number: 9539230
    Abstract: A medical composition for reducing the rate of new-onset diabetes caused by administration of a statin or for inhibiting an increase in blood glucose level by administration of a statin, the composition containing at least one ingredient selected from the group consisting of icosapentaenoic acid and pharmaceutically acceptable salts or esters thereof as an inactive ingredient.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: January 10, 2017
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Masahiko Ohta, Shinichi Oikawa, Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito
  • Publication number: 20160377615
    Abstract: A novel convenient method for evaluating the function of a phagocyte is provided. The method assays sCD14-ST, which is a humoral factor specifically produced in phagocytosis by the phagocyte and which is stable enough for use in an assay. Also provided is a method for detecting diseases associated with the phagocytosis by the phagocyte.
    Type: Application
    Filed: September 7, 2016
    Publication date: December 29, 2016
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventor: Katsuki NAITO
  • Publication number: 20160347751
    Abstract: It has been desired to develop a pharmaceutical composition, which is used in agents for preventing and/or treating various diseases related to PDE10 (e.g. mental disorder and neurodegenerative disorder). The present invention provides: compounds having PDE10 inhibitory effect, in particular, compounds having a 4-heteroarylpyrazole-5-carboxylic acid amide structure represented by the following formula (I), or their pharmaceutically acceptable salts, or their solvates; pharmaceutical compositions comprising, as active ingredients, the compounds, or their pharmaceutically acceptable salts, or their solvates; and medical use of the compounds, or their pharmaceutically acceptable salts, or their solvates.
    Type: Application
    Filed: August 11, 2016
    Publication date: December 1, 2016
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Akihiro OKANO, Kouki OGAWA
  • Patent number: 9486433
    Abstract: Compositions and method are disclosed comprising ethyl icosapentate for use in treatment of non-alcoholic steatohepatitis (NASH).
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: November 8, 2016
    Assignee: Mochida Pharmaceuticals Co. Ltd.
    Inventors: Kiyoshi Mizuguchi, Tsuyoshi Harada, Atsushi Osada, Hiroyuki Kawano, Masayuki Ichioka
  • Patent number: 9476872
    Abstract: A novel convenient method for evaluating the function of a phagocyte is provided. The method assays sCD14-ST, which is a humoral factor specifically produced in phagocytosis by the phagocyte and which is stable enough for use in an assay. Also provided is a method for detecting diseases associated with the phagocytosis by the phagocyte.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: October 25, 2016
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD
    Inventor: Katsuki Naito
  • Patent number: 9458157
    Abstract: It has been desired to develop a pharmaceutical composition, which is used in agents for preventing and/or treating various diseases related to PDE10 (e.g. mental disorder and neurodegenerative disorder). The present invention provides: compounds having PDE10 inhibitory effect, in particular, compounds having a 4-heteroarylpyrazole-5-carboxylic acid amide structure represented by the following formula (I), or their pharmaceutically acceptable salts, or their solvates; pharmaceutical compositions comprising, as active ingredients, the compounds, or their pharmaceutically acceptable salts, or their solvates; and medical use of the compounds, or their pharmaceutically acceptable salts, or their solvates.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: October 4, 2016
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Akihiro Okano, Muneyoshi Makabe, Kouki Ogawa
  • Patent number: 9453015
    Abstract: It has been desired to develop a pharmaceutical composition, which is used in agents for preventing and/or treating various diseases related to PDE10 (e.g. mental disorder and neurodegenerative disorder). The present invention provides: compounds having PDE10 inhibitory effect, in particular, compounds having a 4-heteroarylpyrazole-5-carboxylic acid amide structure represented by the following formula (I), or their pharmaceutically acceptable salts, or their solvates; pharmaceutical compositions comprising, as active ingredients, the compounds, or their pharmaceutically acceptable salts, or their solvates; and medical use of the compounds, or their pharmaceutically acceptable salts, or their solvates.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: September 27, 2016
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Akihiro Okano, Fumihiko Saitoh